Heart fat study could unlock clues to artery disease
NCT ID NCT07360925
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at fat tissue surrounding the heart arteries in 60 patients who had a heart transplant. Researchers want to see if the size of fat cells close to the artery differs from those farther away, and if that relates to artery disease. The goal is to better understand how this fat affects heart health.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors understand how fat around heart arteries affects heart disease, possibly leading to better prevention or treatment strategies.
- What could go wrong
- This is a small, early observational study with only 60 participants. It does not test any treatment, so it may not lead to direct patient benefits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2023
- Expected to finish
-
Jul 2029
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population comprises patients who underwent heart transplantation for heart failure at the Institute for Clinical and Experimental Medicine, Cardiovascular Surgery Department, between June 2023 and December 2028. Only the subjects' ret-rospective clinical data and matching heart samples will be analyzed.
- Ages
-
30 to 90 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 30-90 years * Diagnosis of dilatational or ischemic cardiomyopathy * Patients undergoing heart transplantation in IKEM Exclusion Criteria: * Known combined diagnosis of dilatational and ischemic cardiomyopathy * Arrhythmogenic cardiomyopathy * Congenital heart defects * Non-eligibility due to the absence of informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Dilatational cardiomyopathy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Centre of Experimental Medicine, Institute for Clinical and Experimental Medicine,
RECRUITINGPrague, 14021, Czechia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Thymus cells may teach a new heart to be left alone
- Which SGLT2 inhibitor wins? trial pits empagliflozin against dapagliflozin
- Can a new care pathway speed up advanced heart failure decisions?
- Can daily mindful breathing ease heart failure symptoms?
- Can a smartphone app keep heart failure patients out of the hospital?
- Can better training get doctors to talk about what matters most to dying veterans?